JP2016534048A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534048A5
JP2016534048A5 JP2016522040A JP2016522040A JP2016534048A5 JP 2016534048 A5 JP2016534048 A5 JP 2016534048A5 JP 2016522040 A JP2016522040 A JP 2016522040A JP 2016522040 A JP2016522040 A JP 2016522040A JP 2016534048 A5 JP2016534048 A5 JP 2016534048A5
Authority
JP
Japan
Prior art keywords
cancer
compound according
aryl
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534048A (ja
JP6765302B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/050974 external-priority patent/WO2015051458A1/en
Publication of JP2016534048A publication Critical patent/JP2016534048A/ja
Publication of JP2016534048A5 publication Critical patent/JP2016534048A5/ja
Application granted granted Critical
Publication of JP6765302B2 publication Critical patent/JP6765302B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522040A 2013-10-08 2014-10-08 標的化化学療法に使用するための非白金ベースの抗がん化合物 Expired - Fee Related JP6765302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887988P 2013-10-08 2013-10-08
US61/887,988 2013-10-08
PCT/CA2014/050974 WO2015051458A1 (en) 2013-10-08 2014-10-08 Non-platimun-based anti-cancer compounds for use in targeted chemotherapy

Publications (3)

Publication Number Publication Date
JP2016534048A JP2016534048A (ja) 2016-11-04
JP2016534048A5 true JP2016534048A5 (https=) 2018-02-15
JP6765302B2 JP6765302B2 (ja) 2020-10-07

Family

ID=52812401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522040A Expired - Fee Related JP6765302B2 (ja) 2013-10-08 2014-10-08 標的化化学療法に使用するための非白金ベースの抗がん化合物

Country Status (8)

Country Link
US (2) US10463662B2 (https=)
EP (2) EP3578176A1 (https=)
JP (1) JP6765302B2 (https=)
KR (1) KR102307387B1 (https=)
CN (2) CN114380700A (https=)
AU (1) AU2014334461B2 (https=)
CA (1) CA2926571C (https=)
WO (1) WO2015051458A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
US5620978A (en) * 1994-01-03 1997-04-15 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
DE102004054545A1 (de) * 2004-09-16 2006-04-06 Max-Delbrück-Centrum für Molekulare Medizin Änderung des Beladungszustandes von MHC-Molekülen
US20060089316A1 (en) * 2004-10-25 2006-04-27 Brown Truman R Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
EP1853583B1 (en) * 2005-02-16 2011-09-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
CN101611007A (zh) 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
EP2520561B1 (en) * 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
MX2010001581A (es) * 2007-08-16 2010-03-15 Hoffmann La Roche Hidantoinas substituidas.
DK200801600A (en) * 2008-11-17 2010-05-18 Engkilde Kaare Method for treatment of inflammatory diseases
US8722720B2 (en) * 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
WO2012096813A1 (en) * 2011-01-11 2012-07-19 Merck Sharp & Dohme Corp. Imidazole derivatives
JP6321673B2 (ja) * 2012-12-20 2018-05-09 ルゥ チーン−ビン 放射線と組み合わせて使用するための放射線増感剤化合物

Similar Documents

Publication Publication Date Title
JP2016534048A5 (https=)
JP2019514863A5 (https=)
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
JP2016504325A5 (https=)
JP2019529500A5 (https=)
JP2019535720A5 (https=)
JP2010539095A5 (https=)
JP2017509586A5 (https=)
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
JP2019518766A5 (https=)
JP2020506951A5 (https=)
JP2009534408A5 (https=)
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2008535902A5 (https=)
JP2015512943A5 (https=)
JP2016513137A5 (https=)
JP2017528502A5 (https=)
JP2016518328A5 (https=)
JP2020502268A5 (https=)
JP2014501766A5 (https=)
IL292475A (en) Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
TR201809990T4 (en) NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING.
JP2016537382A5 (https=)
JP2016539985A5 (https=)
JP2015535851A5 (https=)